Lineage Cell reports Q4 net loss $0.17/sh; cash $55.7M; Roche deal up to $670M

Lineage Cell Therapeutics, Inc.

Q4 2021 net loss $29.0M ($0.17/sh) vs net income $2.0M ($0.01/sh) in Q4 2020; FY 2021 net loss $43.0M ($0.26/sh).
Cash and equivalents $55.7M at Dec 31, 2021; received $50M upfront from Roche/Genentech OpRegen collaboration in Jan 2022.
Roche/Genentech deal for OpRegen (RG6501) worth up to $670M plus double-digit royalties; four dry AMD patients showed retinal restoration.
R&D expenses $24.8M in Q4, driven by $21.0M accrual for future obligations to Israel Innovation Authority and Hadasit.
2022 milestones include new pipeline program announcement, OPC1 manufacturing improvements, and VAC2 IND submission in 2H 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.